Despite modern sequencing methods, determining the precise sequence of the genetic code for ribosomal RNA (rRNA) has been technically challenging due…
Valneva announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine,…
Changes in daylength are a well-established annual timing cue for animal behavior and physiology. An international collaboration of scientists led by…
Valneva announced it has appointed Perry Celentano as Chief Operating Officer (COO) on an interim basis to support the expansion of the manufacturing…
New toxin-antidote pairs discovered in nematode species – researchers from the Burga lab at IMBA – Institute of Molecular Biotechnology of the…
Valneva reported preliminary and unaudited cash and cash equivalents of €204.4 million at the end of December 2020, exceeding its guidance of between…
The Austrian Science Fund (FWF) has granted a second four-year funding period for the Doctoral Program “Signaling Mechanisms in Cellular Homeostasis”…
Valneva announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Read more
Nicolas Rivron, group leader at IMBA - Institute of Molecular Biotechnology of the Austrian Academy of Sciences receives an ERC consolidator grant to…
Group leader Joao Matos, who was recently recruited to the Perutz, has been awarded a prestigious ERC Consolidator Grant. The funding, a total of 2…
Not every cluster that is popping up these days is a bad thing: located right in the heart of the Vienna BioCenter, the newly installed Cloud…
Eveliqure Biotechnologies announced the publication of preclinical data with ShigETEC, its vaccine candidate against Shigellae and Enterotoxic E. coli…
